<DOC>
	<DOCNO>NCT00423046</DOCNO>
	<brief_summary>HPV infection establish necessary cause cervical cancer . GSK Biologicals develop HPV-16/18 L1 VLP AS04 vaccine ( Cervarix TM ) target 2 common oncogenic HPV type ( HPV-16 HPV-18 ) , find &gt; 70 % , approximately , cervical cancer . Recently , Merck 's HPV vaccine Gardasil速 [ quadrivalent human papillomavirus ( HPV-6,11,16,18 L1 VLP ) recombinant vaccine ] approve FDA prevention genital tract cancer pre-cancers genital wart female . Although GSK HPV vaccine Gardasil速 different composition expect different efficacy profile , vaccine target prevention HPV-16 18 genital tract cancer pre-cancers . Therefore , comparison immunogenicity two vaccine warrant . This Phase 3b study design compare immunogenicity GSK vaccine ( HPV-16/18 ) Gardasil速 healthy adult females 18-45 year age . The Protocol Posting update study extend 3 additional year .</brief_summary>
	<brief_title>Immunogenicity GlaxoSmithKline Biological 's Human Papillomavirus ( HPV ) Vaccine ( 580299 ) Versus Merck 's Gardasil速 Healthy Females 18-45 Years Age</brief_title>
	<detailed_description>This Protocol Posting update follow Protocol Amendment 25 , November 2010</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A woman investigator believe legally acceptable representative ( event subject illiterate ) comply requirement protocol ( e.g. , completion diary card , return followup visit ) . A woman include 18 45 year age time first vaccination . Written informed consent must obtain subject prior enrollment . Subject must free obvious health problem establish medical history historydirected clinical examination enter study . Subject must negative urine pregnancy test . Subject must nonchildbearing potential , child bear potential , must practice adequate contraception 30 day prior vaccination , negative pregnancy test continue precaution 2 month completion vaccination series . Subject must intact cervix . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period Month 60 . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior first vaccine dose plan administration study period Month 60 . Planned administration/administration vaccine foreseen study protocol within 30 day 30 day ( i.e . day 029 ) dose vaccine . Administration routine vaccine 8 day dose study vaccine allow . Enrolment defer subject outside specify window . Pregnant breastfeeding . Women must least 3 month postpregnancy breastfeed enter study . A woman plan become pregnant planning discontinue contraceptive precaution approximately first eight month study ( Months 08 ) . Previous administration component investigational vaccine Previous plan vaccination HPV outside protocol . Any medically diagnose suspected immunodeficient condition base medical history physical examination . History allergic disease , suspect allergy reaction likely exacerbate component study vaccine . Hypersensitivity latex . Known acute chronic , clinically significant pulmonary , cardiovascular , neurologic , hepatic renal functional abnormality , determine previous physical examination laboratory test . History significant medical condition currently treatment . Received immunoglobulin and/or blood product within 90 day precede enrolment plan administration study period Month 60 . Enrollment defer subject outside specify window . Acute disease time enrolment . Enrollment deferred condition resolve . All vaccine administer person minor illness Heavy bleeding ( menstruation ) heavy vaginal discharge pelvic exam perform . Enrollment deferred condition resolve accord investigator 's medical judgement .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Vaccines</keyword>
	<keyword>Cervical cancer</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Humans</keyword>
	<keyword>Safety</keyword>
	<keyword>Viral infection</keyword>
	<keyword>Human papillomavirus ( HPV )</keyword>
	<keyword>Comparative study</keyword>
	<keyword>Human papillomavirus vaccine</keyword>
	<keyword>Adults</keyword>
</DOC>